Tinted Nannicha, Pongcharoenwanit Smith, Ongvisespaibool Thodsapol, Wachirodom Veerada, Jumnansilp Taksaon, Buckland Narinthip, Chuchalermporn Piyathip, Soontararak Sirikul, Pairor Selapoom, Steiner Jörg M, Thengchaisri Naris, Assawarachan Sathidpak Nantasanti
Internal Medicine Unit, Kasetsart University Veterinary Teaching Hospital, Faculty of Veterinary Medicine, Kasetsart University, 50 Ngamwongwan Rd., Lat Yao, Jatujak, Bangkok 10900, Thailand.
Department of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine, Kasetsart University, 50 Ngamwongwan Rd., Lat Yao, Jatujak, Bangkok 10900, Thailand.
Animals (Basel). 2023 Oct 18;13(20):3244. doi: 10.3390/ani13203244.
Hyperadrenocorticism (HAC) often leads to vacuolar hepatopathy. The impact of trilostane treatment on serum total bile acids (SBAs) concentrations in dogs with HAC remains unknown. This study investigated SBAs concentrations in healthy dogs and those with HAC following trilostane therapy. Ten healthy dogs and fifteen dogs with HAC were prospectively enrolled. A biochemistry profile and pre- and post-prandial SBAs concentrations were determined in each dog. Dogs with HAC were reassessed at 1 and 3 months after the initiation of trilostane treatment. Dogs with HAC had significantly higher serum ALT, ALP, and GGT activities, and cholesterol, triglyceride, and pre-prandial SBAs concentrations compared to healthy dogs. After 3 months of trilostane treatment, polyuria/polydipsia and polyphagia were completely resolved in 42.8% and 35.7%, respectively. Significant improvements in serum ALT and ALP activities and cholesterol concentrations were observed within 1-3 months of trilostane treatment. However, pre- and post-prandial SBAs concentrations did not significantly decrease. These findings suggest that treatment with low-dose trilostane for 3 months appears to reduce serum liver enzyme activities, but not SBAs concentrations. Further investigation is warranted to explore the effects of low-dose trilostane treatment on SBAs concentrations for a longer duration or after achieving appropriate post-ACTH cortisol levels.
肾上腺皮质功能亢进（HAC）常导致空泡性肝病。曲洛司坦治疗对患有HAC的犬血清总胆汁酸（SBA）浓度的影响尚不清楚。本研究调查了健康犬和接受曲洛司坦治疗的患有HAC的犬的SBA浓度。前瞻性纳入了10只健康犬和15只患有HAC的犬。测定每只犬的生化指标以及餐前和餐后SBA浓度。对患有HAC的犬在开始曲洛司坦治疗后的1个月和3个月进行重新评估。与健康犬相比，患有HAC的犬血清ALT、ALP和GGT活性以及胆固醇、甘油三酯和餐前SBA浓度显著更高。曲洛司坦治疗3个月后，多尿/多饮和多食分别在42.8%和35.7%的犬中完全缓解。在曲洛司坦治疗的1 - 3个月内观察到血清ALT和ALP活性以及胆固醇浓度有显著改善。然而，餐前和餐后SBA浓度没有显著降低。这些发现表明，低剂量曲洛司坦治疗3个月似乎可降低血清肝酶活性，但不能降低SBA浓度。有必要进一步研究以探讨低剂量曲洛司坦治疗在更长时间或达到适当的促肾上腺皮质激素刺激后皮质醇水平后对SBA浓度的影响。
